Case Study: Complete Hair Regrowth and Repigmentation in an 11-Year-Old with Alopecia Totalis Following JAK Inhibitor Treatment
By
Yanhong Jia
Xue Wang
Yuanxiang Liu
Zigang Xu
Bin Zhang
July 16, 2026
Clinical Scorecard: Case Study: Complete Hair Regrowth and Repigmentation in an 11-Year-Old with Alopecia Totalis Following JAK Inhibitor Treatment
At a Glance
Category Detail
Condition Alopecia areata Key Mechanisms JAK inhibitors targeting JAK1/2 and JAK3/TEC Target Population Pediatric patients with severe alopecia areata Care Setting Dermatology clinic
Key Highlights
Complete hair regrowth and repigmentation observed in an 11-year-old girl with alopecia totalis. Initial treatment with baricitinib led to SALT 65% with predominantly white and gray hair. Switching to ritlecitinib resulted in black hair emergence at 6 weeks and complete regrowth at 6 months. Family Dermatology Life Quality Index (FDLQI) improved from 18 to 4. No significant adverse effects reported during treatment. Guideline-Based Recommendations
Diagnosis
Diagnosis of alopecia areata confirmed through clinical evaluation. Management
Initial treatment with baricitinib followed by ritlecitinib for incomplete response. Monitoring & Follow-up
Regular monthly follow-up visits to monitor hair regrowth and side effects. Risks
No significant side effects reported; laboratory tests remained within normal limits. Patient & Prescribing Data
Children with severe alopecia areata, specifically alopecia totalis.
Sequential JAK inhibitor therapy may facilitate hair regrowth and pigment restoration.
Clinical Best Practices
Consider JAK inhibitors for severe cases of alopecia areata in pediatric patients. Monitor quality of life using validated instruments like FDLQI. Related Resources & Content
